Gabelli & CO Investment Advisers, Inc. Gracell Biotechnologies Inc. Call Options Transaction History

Gabelli & CO Investment Advisers, Inc.

  • $535 Million
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Gabelli & CO Investment Advisers, Inc. Portfolio

Follow Gabelli & CO Investment Advisers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gabelli & CO Investment Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gabelli & CO Investment Advisers, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email